Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, PROTALIX BIOTHERAPEUTICS, INC. reported revenue of $53M, down 1.2% year over year. Operating margin was -10.4% and net margin -12.5%, on a free-cash-flow margin of -25.8% with capital expenditure at 3.1% of revenue. Every figure is computed directly from PLX's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $53M | -10.4% | -12.5% |
| FY2024 | $53M | 7.3% | 5.5% |
| FY2023 | $65M | 16.0% | 12.7% |
| FY2022 | $48M | -27.3% | -31.3% |
| FY2021 | $38M | -53.4% | -71.9% |
How does PLX compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: AAWH · ABBV · ABCL · ABT · ABUS · ACAD
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.